AKAO Achaogen Inc.

Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019

Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019

SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it will report its fourth quarter financial results on Thursday, March 28, 2019 after the open of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, March 28, 2019

  • 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
  • Telephone 800-347-6311 (domestic) or 323-994-2131 (international); conference ID 3056397
  • Webcast available at

REPLAY access

  • Telephone replay will be available for 30 days beginning at 7:30 p.m. ET on Thursday, March 28 by calling 844-512-2921 (domestic) or 412-317-6671 (international); conference ID 3056397
  • Webcast replay will be available on the Achaogen website at and will be archived for 30 days following the presentation

About Achaogen

Achaogen is a biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram negative infections. Achaogen’s first commercial product is ZEMDRI, for the treatment of adults with complicated urinary tract infections, including pyelonephritis. The Achaogen ZEMDRI program was funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). The Company is currently developing C-Scape, an orally administered beta-lactam/beta-lactamase inhibitor combination, which is also supported by BARDA.  C-Scape is investigational, has not been determined to be safe or efficacious, and has not been approved for commercialization. For more information, visit the Achaogen website at .

Source: Achaogen, Inc.

© 2019 Achaogen, Inc. All Rights Reserved.

Media and Investor Contact

Denise T. Powell
Red House Consulting, LLC
 
EN
13/03/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Achaogen Inc.

 PRESS RELEASE

Achaogen, Inc. Announces Results of Auction for Substantially All Comp...

Achaogen, Inc. Announces Results of Auction for Substantially All Company Assets SOUTH SAN FRANCISCO, Calif., June 06, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today it has reached agreements to sell substantially all of its assets for aggregate cash consideration of approximately $16 million, plus potential royalties and assumption of certain contractual liabilities, subject to negotiation and execution of binding definitive ...

 PRESS RELEASE

Achaogen Plans for Near-Term Sale Using Structured Process Through Cha...

Achaogen Plans for Near-Term Sale Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code Bidding process and auction projected to conclude June 2019 SOUTH SAN FRANCISCO, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today that it has filed a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Achaogen ha...

Ashiq Mubarack ... (+3)
  • Ashiq Mubarack
  • David Nierengarten
  • Robert Driscoll
 PRESS RELEASE

Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results a...

Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update -- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic alternatives -- -- Conference call today at 4:30 p.m. Eastern Time -- SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negati...

Ashiq Mubarack ... (+6)
  • Ashiq Mubarack
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe
ZFGN ZAFGEN
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XNCR XENCOR INC.
VYGR VOYAGER THERAPEUTICS INC.
STML STEMLINE THERAPEUTICS INC
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
OMER OMEROS CORPORATION
NVCR NOVOCURE LTD.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
IRWD IRONWOOD PHARMACEUTICALS INC. CLASS A
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
AKAO ACHAOGEN INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ABUS ARBUTUS BIOPHARMA CORP.
ALPN ALPINE SELECT AG
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
BOLD AUDENTES THERAPEUTICS INC.
MGEN MIRAGEN THERAPEUTICS
SRRA SIERRA ONCOLOGY
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
NBRV NABRIVA THERAPEUTICS PLC
MRSN MERSANA THERAPEUTICS
SYBX SYNLOGIC
GTHX G1 THERAPEUTICS
VRNA VERONA PHARMA ADS
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
RCUS ARCUS BIOSCIENCES
TORC RESTORBIO INC
UMRX UNUM THERAPEUTICS
IDRA IDERA PHARMACEUTICALS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
MGTA MAGENTA THERAPEUTICS
ETTX ENTASIS THERAPEUTICS HOLDINGS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
ORTX INC.
HARP ORCHARD THERAPEUTICS
FENC HARPOON THERAPEUTICS
FENNEC PHARMA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch